James Jerkins is an Oncology physician affiliated with Vanderbilt University. OpenAlex indexes 58 publications with 502 citations (h-index 13).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 372323522
Telephone
615-322-5000Provider last certified this registry record 9 Oct 2024.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20231 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
49.6%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor25.4%Valacyclovir100%Part D≥21 patientsAzole Antifungal7.3%Fluconazole100%Part D≥14 patients+ 3 more classes in this area
Cancer & immunology
19.4%Kinase inhibitor14.5%Jakafi69%Imbruvica31%Part D<11 patientsBCR-ABL tyrosine kinase inhibitors4.8%Scemblix100%Part D<11 patientsMetabolism & gastrointestinal
13.7%Serotonin-3 Receptor Antagonist7.7%Ondansetron Hcl100%Part D≥17 patientsProton pump inhibitor6%Omeprazole100%Part D≥15 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outpatient Chimeric Antigen Receptor T cell Therapy in Patients Who Resided at Their Home Compared to Hospital-Provided Housing: A Single Institution Experience
Biology of Blood and Marrow Transplantation
2026 - Impact of Intrathecal Therapy on Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) Compared to a Historical Cohort: A Single Center Analysis
Biology of Blood and Marrow Transplantation
2026 - Platelet-Targeted Gene Therapy for Hemophilia A with Inhibitor History
New England Journal of Medicine
2025 - Feasibility of axicabtagene ciloleucel in the outpatient setting: primary analysis of prospective trial
Bone Marrow Transplantation
2025 - Impact of Granulocyte Colony Stimulating Factor Use Following CD-19 Chimeric Antigen Receptor T-Cell Therapy
Biology of Blood and Marrow Transplantation
2025
Similar KOLs
Other experts from the same institution or the same specialty.
William Schaffner, MD
Vanderbilt University
Keith Obstein, MD, MPH
Vanderbilt University
Andrew Jallouk, MD, PhD
Vanderbilt University
Salim Yusuf
Vanderbilt University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”